Cargando…
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Clinical samples were tested for EGFR mutations by peptide nucleic acid-locked nucleic acid PCR clamp, and patients...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360739/ https://www.ncbi.nlm.nih.gov/pubmed/17106442 http://dx.doi.org/10.1038/sj.bjc.6603466 |
_version_ | 1782153123448487936 |
---|---|
author | Sutani, A Nagai, Y Udagawa, K Uchida, Y Koyama, N Murayama, Y Tanaka, T Miyazawa, H Nagata, M Kanazawa, M Hagiwara, K Kobayashi, K |
author_facet | Sutani, A Nagai, Y Udagawa, K Uchida, Y Koyama, N Murayama, Y Tanaka, T Miyazawa, H Nagata, M Kanazawa, M Hagiwara, K Kobayashi, K |
author_sort | Sutani, A |
collection | PubMed |
description | This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Clinical samples were tested for EGFR mutations by peptide nucleic acid-locked nucleic acid PCR clamp, and patients having EGFR mutations were given gefitinib 250 mg daily as the second treatment after chemotherapy. Poor PS patients omitted chemotherapy. Of 107 consecutive patients enrolled, samples from 100 patients were informative, and EGFR mutations were observed in 38 patients. Gefitinib was given to 27 patients with EGFR mutations, and the response rate was 78% (one complete response and 20 partial responses; 95% confidence interval: 58–93%). Median time to progression and median survival time (MST) from gefitinib treatment were 9.4 and 15.4 months, respectively. Grade 3 hepatic toxicity and skin toxicity were observed in one patient each. There were significant differences between EGFR mutations and wild-type patients in response rates (78 vs 14%, P=0.0017), and MST (15.4 vs 11.1 months, P=0.0135). A Cox proportional hazards model indicated that negative EGFR mutation was a secondary prognostic factor (hazards ratio: 2.259, P=0.036). This research showed the need for screening for EGFR mutations in NSCLC patients. |
format | Text |
id | pubmed-2360739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23607392009-09-10 Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp Sutani, A Nagai, Y Udagawa, K Uchida, Y Koyama, N Murayama, Y Tanaka, T Miyazawa, H Nagata, M Kanazawa, M Hagiwara, K Kobayashi, K Br J Cancer Clinical Study This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Clinical samples were tested for EGFR mutations by peptide nucleic acid-locked nucleic acid PCR clamp, and patients having EGFR mutations were given gefitinib 250 mg daily as the second treatment after chemotherapy. Poor PS patients omitted chemotherapy. Of 107 consecutive patients enrolled, samples from 100 patients were informative, and EGFR mutations were observed in 38 patients. Gefitinib was given to 27 patients with EGFR mutations, and the response rate was 78% (one complete response and 20 partial responses; 95% confidence interval: 58–93%). Median time to progression and median survival time (MST) from gefitinib treatment were 9.4 and 15.4 months, respectively. Grade 3 hepatic toxicity and skin toxicity were observed in one patient each. There were significant differences between EGFR mutations and wild-type patients in response rates (78 vs 14%, P=0.0017), and MST (15.4 vs 11.1 months, P=0.0135). A Cox proportional hazards model indicated that negative EGFR mutation was a secondary prognostic factor (hazards ratio: 2.259, P=0.036). This research showed the need for screening for EGFR mutations in NSCLC patients. Nature Publishing Group 2006-12-04 2006-11-14 /pmc/articles/PMC2360739/ /pubmed/17106442 http://dx.doi.org/10.1038/sj.bjc.6603466 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Sutani, A Nagai, Y Udagawa, K Uchida, Y Koyama, N Murayama, Y Tanaka, T Miyazawa, H Nagata, M Kanazawa, M Hagiwara, K Kobayashi, K Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp |
title | Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp |
title_full | Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp |
title_fullStr | Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp |
title_full_unstemmed | Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp |
title_short | Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp |
title_sort | gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid pcr clamp |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360739/ https://www.ncbi.nlm.nih.gov/pubmed/17106442 http://dx.doi.org/10.1038/sj.bjc.6603466 |
work_keys_str_mv | AT sutania gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT nagaiy gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT udagawak gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT uchiday gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT koyaman gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT murayamay gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT tanakat gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT miyazawah gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT nagatam gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT kanazawam gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT hagiwarak gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp AT kobayashik gefitinibfornonsmallcelllungcancerpatientswithepidermalgrowthfactorreceptorgenemutationsscreenedbypeptidenucleicacidlockednucleicacidpcrclamp |